🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Kidney Diseases

Prevention of Nephrotoxin-Induced Acute Kidney Injury Using Cilastatin NCT06886464Phase 22 sites📍 Calgary📍 Edmonton Matthew James · Tests: Cilastatin Sodium, Placebo-Saline Nephrotic Syndrome Study Network NCT01209000n/a44 sites📍 Los Angeles📍 Palo Alto📍 San Francisco University of Michigan · Tests: Kidney Biopsy Diabetic Nephropathy in People With Diabetes. Prevalence and Predictive Factors NCT04916132n/a13 sites📍 Skejby📍 Copenhagen📍 Hillerød Herlev Hospital · Tests: Kidney Biopsy Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease NCT06497387EARLY Phase 11 site📍 Wuhan Tongji Hospital · Tests: PRG-1801 Protecting Kidneys Through a Low Protein Diet: A Stepwise Multiple-Choice System Approach NCT03979534NA2 sites📍 La Flèche📍 Le Mans Centre Hospitalier le Mans · Tests: low protein diet A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis NCT07499700Phase 2, Phase 31 site📍 Beijing Bio-Thera Solutions · Tests: BAT4406F, Placebos Effect of Montelukast on Kidney and Vascular Function in Type 1 Diabetes NCT05498116Phase 41 site📍 Aurora University of Colorado, Denver · Tests: Montelukast, Placebo A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies NCT07195916Phase 122 sites📍 Duarte📍 La Jolla📍 Ann Arbor Incyte Corporation · Tests: INCA036873 A Study to Investigate the Safety, Tolerability, and Preliminary Efficacy With AION-301 Administered by Intravenous Infusion Compared With Placebo Administered by Intravenous Infusion Investigational Intervention in Participants Aged 35 to 75 Years of Age With Chronic Kidney Disease (CKD) NCT06721143Phase 1, Phase 22 sites📍 Miami📍 Miami AION Healthspan, Inc. · Tests: AION-301, Placebo WIRE - Novel Treatments in Renal Cell Cancer NCT03741426Phase 27 sites📍 Cambridge📍 Edinburgh📍 Exeter CCTU- Cancer Theme · Tests: Olaparib, Cediranib, Volrustomig, Rilvegostomig Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford NCT01793168n/a1 site📍 Sioux Falls Sanford Health Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria NCT03301038Phase 21 site📍 Philadelphia Children's Hospital of Philadelphia · Tests: Rifampin Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal Cell NCT07062549Phase 11 site📍 Baltimore Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Tests: 111In-XYIMSR-01 WISDOM UK: Low Dose-intensity Versus Standard Dose-intensity CRRT in Critically Ill Patients NCT07447791NA1 site📍 London Guy's and St Thomas' NHS Foundation Trust · Tests: low intensity of CRRT, usual intensity of CRRT Impact of Chronic Renal Failure on Plasma Exposure of Kinase Inhibitors in Patients Treated for Metastatic Kidney Cancer NCT04823923NA5 sites📍 Marseille📍 Montpellier📍 Montpellier Institut du Cancer de Montpellier - Val d'Aurelle · Tests: blood sampling for ITK dosage Early PKD Observational Cohort Study NCT02936791n/a3 sites📍 Chicago📍 Kansas City📍 Kansas City University of Kansas Medical Center 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors NCT07557225NA1 site📍 Beijing Peking University First Hospital · Tests: 18F-T2 PET/CT To Compare the Efficacy and Safety of Using oXiris and M100 During CRRT NCT06440759NA1 site📍 Kubang Kerian Mohd Zulfakar Mazlan, MBBS · Tests: oXiris filter, M100 filter Testosterone Treatment in Men With Chronic Kidney Disease NCT05249634Phase 21 site📍 St Louis St. Louis University · Tests: Jatenzo Pill Acute Kidney Injury In Care Transitions (ACT): Pragmatic Clinical Trial NCT07670520NA3 sites📍 Mankato📍 Rochester📍 Eau Claire Mayo Clinic · Tests: Acute Kidney Injury in Care Transitions (ACT), Usual Care Hamburg Acute Kidney Injury Study (HAKIS) NCT07338669n/a1 site📍 Hamburg Universitätsklinikum Hamburg-Eppendorf Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients NCT06824454Phase 21 site📍 Stanford Stanford University · Tests: Dipyridamole 75 MG New Taipei City 888 Digital Medical AI Platform for Prevention and Care of the Three Highs and Cardio-Renal-Vascular Diseases NCT07588256NA1 site📍 New Taipei City New Taipei City Medical Association · Tests: Interactive digital modules, Antihypertensive Medication Management The Role of Renal Progenitors and Polyploid Tubular Cell Response in Glomerular and Tubular Diseases NCT06325059NA1 site📍 Florence Meyer Children's Hospital IRCCS · Tests: Study of renal progenitors Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology NCT05756569Phase 24 sites📍 Atlanta📍 Atlanta📍 Atlanta Emory University · Tests: Biospecimen Collection, Computed Tomography, Enfortumab Vedotin, Magnetic Resonance Imaging, Pembrolizumab An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant NCT06832410Phase 37 sites📍 Philadelphia📍 Pittsburgh📍 Madison Vertex Pharmaceuticals Incorporated · Tests: Biological/Vaccine Optimizing Pulsatility During Cardiopulmonary Bypass NCT05344573n/a1 site📍 Aurora University of Colorado, Denver Clinical Evaluation of [68Ga]Ga-XT771 PET for Diagnosis in Patients With Glioblastoma and Clear Cell Renal Cell Carcinoma NCT07067905EARLY Phase 11 site📍 Beijing Chinese PLA General Hospital · Tests: 68Ga-XT771 LCAT (Lecithin Cholesterol Acyl Transferase) Natural History Study NCT06217588n/a1 site📍 Philadelphia University of Pennsylvania · Tests: Demographics, diagnosis type, genotype, lipid profile, renal function profile, treatment allocation, ophthalmology exam… Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma NCT07223541Phase 21 site📍 Oklahoma City University of Oklahoma · Tests: Cemiplimab 350 MG Intravenous Solution, Fianlimab 1600 MG Intravenous Solution
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy